34 results on '"Nikiforow, Sarah"'
Search Results
2. Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
3. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
4. Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse
5. Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
6. Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis
7. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
8. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease
9. Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease
10. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial
11. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
12. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
13. Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution
14. Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival
15. Tabelecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol
16. Active infection at the time of CD34+selected stem cell boost is associated with treatment failure and poor overall survival
17. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience
18. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide
19. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
20. BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation
21. Identification of germline variants in adults with hemophagocytic lymphohistiocytosis
22. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children
23. Tabelecleucel for EBV+PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
24. Robust Quality Infrastructure is Key to Safe and Effective Delivery of Immune Effector Cells: How FACT-Finding Can Help
25. A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help
26. Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
27. Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
28. Favorable Outcomes Following Allogeneic Transplantation in Adults with Hemophagocytic Lymphohistiocytosis
29. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia
30. Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation
31. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease
32. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease
33. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients
34. A Robust Quality Infrastructure is Key to Safe and Effective Delivery of Immune Effector Cells – How “FACT”-Finding Can Help
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.